| Date | Title | | | 05/15/13 | Idera Pharmaceuticals Reports First Quarter 2013 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 15, 2013--
Idera
Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial
results for the quarter ended March 31, 2013.
“Our next objective in Idera’s autoimmune disease program is to initiate
a Phase 2 study of IMO-8400, a first-in-class TLR7, 8 and 9 antagonist,
in patients with moderate-to-severe plaque psoriasis during the current
quarter. This study will enable us to evaluate the continued ... |
|  | | 05/08/13 | Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis| PASI Score Improvements Correlated with Downregulation of IL-17
Pathway
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013--
Idera Pharmaceuticals (NASDAQ: IDRA) today announced presentation of
data from its randomized, double-blind, placebo-controlled Phase 2 trial
that showed improvements from baseline of up to 90% in Psoriasis Area
Severity Index (PASI) scores in patients with moderate to severe plaque
psoriasis following four weeks of treatme... |
| | | 05/07/13 | Idera Pharmaceuticals Announces Closing of Common Share Offering| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 7, 2013--
Idera Pharmaceuticals (NASDAQ: IDRA) announced today the closing of its
previously announced $16.5 million underwritten public offering of (i)
17,500,000 shares of common stock and related warrants to purchase up to
17,500,000 shares of common stock at an exercise price of $0.47 per
share, and (ii) pre-funded warrants to purchase up to 15,816,327 shares
of common stock at an exercise price of $0.01 per sh... |
| | | 05/01/13 | Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 1, 2013--
Idera Pharmaceuticals (Nasdaq: IDRA) today announced the pricing of an
underwritten public offering by Idera Pharmaceuticals of (i) for a
combined public offering price of $0.50 per share of common stock and
related warrant, 17,500,000 shares of common stock and related warrants
to purchase up to 17,500,000 shares of common stock at an exercise price
of $0.47 per share, and (ii) for a combined public offe... |
| | | 04/01/13 | Idera Announces Clinical Development Progress in Its Autoimmune Diseases Program| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2013--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that it has
completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects.
In addition, the Company announced that its protocol for a Phase 2 study
of IMO-8400 in patients with psoriasis has received “no objection”
clearance from the Competent Authority of the Netherlands. IMO-8400 is
an antagonist of Toll-like receptors (TLRs) 7, 8 and 9,... |
| | | 03/11/13 | Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease Program| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2013--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported its financial
and operational results for the fourth quarter and year ended December
31, 2012.
“During the past year, Idera has demonstrated promising clinical
activity for the use of Toll-like Receptor antagonists as a novel
approach for the potential treatment of autoimmune diseases,” said
Sudhir Agrawal, D.Phil., Chairman and... |
| | | 03/02/13 | Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis Model|
--Phase 2 Data of IMO-3100 in Psoriasis to be Presented at IID
Meeting 2013--
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2013--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
presentation of new data showing that its selective Toll-like receptor
antagonists, IMO-3100 and IMO-8400, normalized the gene expression of
important cytokines in a preclinical study of skin inflammation that is
commonly used as a model of psorias... |
| | | 02/26/13 | Idera Pharmaceuticals Announces Presentation at American Academy of Dermatology Annual Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2013--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
developing Toll-like receptor targeted drug candidates for the treatment
of autoimmune diseases, today announced a presentation of preclinical
data will be made by its collaborator, Dr. James G. Krueger of The
Rockefeller University, at the Late-Breaking Research Symposium during
the American Academy of Dermatology Annual Meeting bei... |
| | | 02/05/13 | Idera to Present at the 15th Annual BIO CEO and Investor Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2013--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
developing Toll-like receptor targeted product candidates for the
treatment of autoimmune diseases and as vaccine adjuvants, today
announced that its management will be presenting at the 15th Annual BIO
CEO & Investor Conference. Hosted by the Biotechnology Industry
Organization (BIO), the 15th Annual BIO CEO & Investor Confer... |
| |
|
